Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer Journal Article

   

Authors:	Scher, H. I.; Armstrong, A. J.; Schonhoft, J. D.; Gill, A.; Zhao, J. L.; Barnett, E.; Carbone, E.; Lu, J.; Antonarakis, E. S.; Luo, J.; Tagawa, S.; dos Anjos, C. H.; Yang, Q.; George, D.; Szmulewitz, R.; Danila, D. C.; Wenstrup, R.; Gonen, M.; Halabi, S.
Article Title:	Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
Abstract:	Purpose: To evaluate the prognostic significance of circulating tumour cell (CTC) number determined on the Epic Sciences platform in men with metastatic castration-resistant prostate cancer (mCRPC) treated with an androgen receptor signalling inhibitor (ARSI). Patients and methods: A pre-treatment blood sample was collected from men with progressing mCRPC starting either abiraterone or enzalutamide as a first-, second- or third-line systemic therapy at Memorial Sloan Kettering Cancer Center (Discovery cohort, N = 171) or as a first- or second-line therapy as part of the multicenter PROPHECY trial (NCT02269982) (Validation cohort, N = 107). The measured CTC number was then associated with overall survival (OS) in the Discovery cohort, and progression-free survival (PFS) and OS in the Validation cohort. CTC enumeration was also performed on a concurrently obtained blood sample using the CellSearch® Circulating Tumor Cell Kit. Results: In the MSKCC Discovery cohort, CTC count was a statistically significant prognostic factor of OS as a dichotomous (<3 CTCs/mL versus ≥ 3 CTCs/mL; hazard ratio [HR] = 1.8 [95% confidence interval {CI} 1.3–3.0]) and a continuous variable when adjusting for line of therapy, presence of visceral metastases, prostate-specific antigen, lactate dehydrogenase and alkaline phosphatase. The findings were validated in an independent datas et from PROPHECY (HR [95% CI] = 1.8 [1.1–3.0] for OS and 1.7 [1.1–2.9] for PFS). A strong correlation was also observed between CTC counts determined in matched samples on the CellSearch® and Epic platforms (r = 0.84). Conclusion: The findings validate the prognostic significance of pretreatment CTC number determined on the Epic Sciences platform for predicting OS in men with progressing mCRPC starting an ARSI. © 2021
Keywords:	prostate cancer; biomarker; ctc; prognosis
Journal Title:	European Journal of Cancer
Volume:	150
ISSN:	0959-8049
Publisher:	Elsevier Inc.
Date Published:	2021-06-01
Start Page:	83
End Page:	94
Language:	English
DOI:	10.1016/j.ejca.2021.02.042
PROVIDER:	scopus
PUBMED:	33894633
PMCID:	PMC8772024
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104428279&doi=10.1016%2fj.ejca.2021.02.042&partnerID=40&md5=7d475dd837d5aaae05c596558aa63aed
Notes:	Article -- Export Date: 3 May 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/180093